Abstract: A semiconductor device may include a first active fin, a plurality of second active fins, a first source/drain layer structure, and a second source/drain layer structure. The first active fin may be on a first region of a substrate. The second active fins may be on a second region of the substrate. The first and second gate structures may be on the first and second active fins, respectively. The first source/drain layer structure may be on a portion of the first active fin that is adjacent to the first gate structure. The second source/drain layer structure may commonly contact upper surfaces of the second active fins adjacent to the second gate structure. A top surface of the second source/drain layer structure may be further from the surface of the substrate than a top surface of the first source/drain layer structure is to the surface of the substrate.

Abstract: A display panel is provided including a first substrate, an upper structure, and a first conductive pattern. The first substrate may include an upper surface and a lower surface on opposite sides of the first substrate, the upper and lower surfaces facing away from each other. The upper structure may be on the upper surface of the first substrate. A first conductive pattern layer may be on the lower surface of the first substrate. The first conductive pattern layer may be configured to absorb and discharge static electricity input from outside the display panel.

Abstract: A display panel is provided including a first substrate, an upper structure, and a first conductive pattern. The first substrate may include an upper surface and a lower surface on opposite sides of the first substrate, the upper and lower surfaces facing away from each other. The upper structure may be on the upper surface of the first substrate. A first conductive pattern layer may be on the lower surface of the first substrate. The first conductive pattern layer may be configured to absorb and discharge static electricity input from outside the display panel.

Abstract: A semiconductor device includes a substrate, a gate structure disposed on the substrate and which includes a gate insulating layer and a gate electrode layer, a first nitride layer disposed on the substrate and the gate structure and which includes silicon, and a second nitride layer that is disposed on the first nitride layer and has an atomic percentage of silicon less than that of the first nitride layer.

Abstract: Disclosed is a method for fabricating a flexible board using carbon nanotubes. The method includes applying a carbon nanotube-containing ink onto a substrate to form a deposited layer, and coating a polymeric or monomeric solution on the deposited carbon nanotube layer to form a thin film layer. In accordance with the method, the spin-coated carbon nanotube layer is coated with the polymeric or monomeric chemical solution to minimize an area where the base substrate contacts the polymeric film and thereby to advantageously form a flexible board readily separable from the substrate without applying any external stress or laser.

Abstract: The present invention relates to a composition containing vitamin C. The composition according to the present invention includes cationic material and anionic material as a primary stabilizing agent of the vitamin C; and a caffeic acid derivative as a secondary stabilizing agent of the vitamin C. The caffeic acid derivative is water-soluble and, preferably, a new caffiec acid derivative as denoted by the chemical formula 1 below is used. According to the present invention, the cationic material and the anionic material generate an electrical double layer to stabilize the vitamin C primarily; water-soluble caffeic acid derivative stabilizes the vitamin C secondarily. Accordingly, the vitamin C is stabilized double so that the vitamin C is protected from being oxidized by air, heat and moisture.

Abstract: Disclosed herein is a pharmaceutical composition for the prophylaxis and treatment of restenosis, comprising a peroxiredoxin 2 (Prx II) protein as an active ingredient. Optionally, the composition may contain other active ingredients suppressive of restenosis at the carotid artery, the coronary artery, the peripheral artery, and the renal artery. Also, a composition and a method are provided for screening therapeutics for restenosis. This screening composition comprises a peroxiredoxin 2 gene or protein. Together with the method, the composition is useful for searching and developing therapeutics for restenosis.

Abstract: Disclosed herein is a pharmaceutical composition for the prophylaxis and treatment of restenosis, comprising a peroxiredoxin 2 (Prx II) protein as an active ingredient. Optionally, the composition may contain other active ingredients suppressive of restenosis at the carotid artery, the coronary artery, the peripheral artery, and the renal artery. Also, a composition and a method are provided for screening therapeutics for restenosis. This screening composition comprises a peroxiredoxin 2 gene or protein. Together with the method, the composition is useful for searching and developing therapeutics for restenosis.

Abstract: The present invention relates to a composition containing vitamin C. The composition according to the present invention includes cationic material and anionic material as a primary stabilizing agent of the vitamin C; and a caffeic acid derivative as a secondary stabilizing agent of the vitamin C. The caffeic acid derivative is water-soluble and, preferably, a new caffiec acid derivative as denoted by the chemical formula 1 below is used. According to the present invention, the cationic material and the anionic material generate an electrical double layer to stabilize the vitamin C primarily; water-soluble caffeic acid derivative stabilizes the vitamin C secondarily. Accordingly, the vitamin C is stabilized double so that the vitamin C is protected from being oxidized by air, heat and moisture.

Abstract: Disclosed herein is a pharmaceutical composition for the prophylaxis and treatment of restenosis, comprising a peroxiredoxin 2 (Prx II) protein as an active ingredient. Optionally, the composition may contain other active ingredients suppressive of restenosis at the carotid artery, the coronary artery, the peripheral artery, and the renal artery. Also, a composition and a method are provided for screening therapeutics for restenosis. This screening composition comprises a peroxiredoxin 2 gene or protein. Together with the method, the composition is useful for searching and developing therapeutics for restenosis.